EIGER BIOPHARMACEUTICALS INC's ticker is EIGR and the CUSIP is 28249U105. A total of 82 filers reported holding EIGER BIOPHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.16 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $2,259,000 | +19.5% | 300,000 | 0.0% | 2.74% | +19.3% |
| Q2 2022 | $1,890,000 | -24.1% | 300,000 | 0.0% | 2.30% | +58.6% |
| Q1 2022 | $2,490,000 | +67.5% | 300,000 | +4.7% | 1.45% | +46.5% |
| Q4 2021 | $1,487,000 | -8.8% | 286,459 | +17.4% | 0.99% | -16.7% |
| Q3 2021 | $1,630,000 | -21.6% | 244,081 | 0.0% | 1.19% | -17.3% |
| Q2 2021 | $2,080,000 | +4.0% | 244,081 | +8.0% | 1.44% | +38.7% |
| Q1 2021 | $2,000,000 | -21.2% | 226,000 | +9.5% | 1.04% | -50.5% |
| Q4 2020 | $2,537,000 | +55.8% | 206,404 | +3.2% | 2.09% | +25.5% |
| Q3 2020 | $1,628,000 | -5.1% | 200,000 | +11.9% | 1.67% | -10.2% |
| Q2 2020 | $1,716,000 | +62.0% | 178,799 | +14.8% | 1.86% | -2.2% |
| Q1 2020 | $1,059,000 | +11.4% | 155,799 | +144.0% | 1.90% | +19.3% |
| Q4 2019 | $951,000 | +9.2% | 63,850 | -24.9% | 1.59% | +82.5% |
| Q3 2019 | $871,000 | +19.0% | 85,000 | +23.0% | 0.87% | -11.9% |
| Q2 2019 | $732,000 | – | 69,079 | – | 0.99% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| P.A.W. CAPITAL CORP | 540,000 | $4,482,000 | 4.68% |
| Knoll Capital Management, LLC | 694,232 | $5,762,000 | 3.62% |
| Telemetry Investments, L.L.C. | 213,000 | $1,768,000 | 2.79% |
| ACT CAPITAL MANAGEMENT, LLC | 250,000 | $2,075,000 | 2.20% |
| VR Adviser, LLC | 1,469,767 | $12,199,000 | 1.98% |
| INTERWEST VENTURE MANAGEMENT CO | 560,990 | $4,656,000 | 1.78% |
| 683 Capital Management, LLC | 3,375,000 | $28,013,000 | 1.50% |
| Trellus Management Company, LLC | 300,000 | $2,490,000 | 1.45% |
| Altium Capital Management LP | 440,000 | $3,652,000 | 1.22% |
| CAXTON CORP | 116,884 | $970,000 | 1.21% |